PCM
MRVI icon

Prelude Capital Management’s Maravai LifeSciences MRVI Stock Holding History

Prelude Capital Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-91,250
Closed -$758K – 1427
2024
Q3 		$758K Buy
+91,250
New +$789K 0.05% 467
2023
Q2 		– Sell
-10,968
Closed -$154K – 1274
2023
Q1 		$154K Sell
10,968
-1,500
-12% -$21.5K 0.01% 904
2022
Q4 		$178K Buy
+12,468
New +$196K 0.01% 996

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's MRVI Position: Q4 2024 in Review

Prelude Capital Management sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 91,250 shares — an estimated $758K sold.

Prelude Capital Management first reported a position in MRVI in Q4 2022 and held it in 3 quarters. The position peaked at $758K in Q3 2024. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

  • Prelude Capital Management reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 91,250 Maravai LifeSciences shares in Q4 2024, an estimated $758K.
  • Prelude Capital Management first reported a position in Maravai LifeSciences in Q4 2022 and held it in 3 quarters.
  • Prelude Capital Management's Maravai LifeSciences position peaked at $758K in Q3 2024.
  • 185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.